NYXH
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah SA (NYXH) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A-); its weakest is Momentum (D-). The rating has held at C+ for 3 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (3.0) | A- (4.1) | B- (2.9) | D- (1.1) | C+ (2.6) | C+ (2.8) |
| 2026-11-06 | B- (3.0) | A (4.3) | B- (3.0) | D- (1.1) | C+ (2.7) | C+ (2.8) |
| 2026-10-30 | B- (3.0) | A (4.2) | B- (3.0) | D (1.2) | C+ (2.7) | C+ (2.8) |
| 2026-10-23 | B- (3.0) | A (4.2) | B- (3.0) | D- (1.0) | C+ (2.6) | C+ (2.8) |
| 2026-10-16 | B- (3.0) | A (4.2) | B- (3.0) | D (1.5) | C+ (2.6) | B- (2.9) |